NTX-101 / PinotBio - LARVOL DELTA

Nitrase Therapeutics Presents Preclinical Data Demonstrating Antibody Prevents Spread of Pathology of Parkinson’s Disease at SfN’s Neuroscience 2024 Scientific Congress (GlobeNewswire) - "Nitrase Therapeutics, Inc...today announced a poster titled 'NTX101, an Antibody Against Nitrated Alpha-Synuclein, Prevents Spread of Pathology in Multiple Pre-Clinical Parkinson Models' (abstract # 6647) was presented at the Society for Neuroscience’s (SfN) Neuroscience 2024 congress taking place in Chicago from October 5-9, 2024. The antibody, which is designed to block the pathological spread of nitrated alpha synuclein (-synuclein), has demonstrated efficacy in multiple in vivo Parkinson’s disease (PD) spread models, further supporting the role of nitrated -synuclein as a pathogenic subspecies driving aggregate spread of PD in the brain...'Based on our impressive body of data showing efficacy in multiple highly-translational Parkinson’s models, we are advancing our humanized antibody NDC-0524 through IND-enabling studies to initiate a clinical study in 2025.'"

Preclinical • CNS Disorders • Parkinson's Disease

Safety and Tolerability of NTX-101 in Korean Healthy Volunteers (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: Pinotbio, Inc. | Active, not recruiting ➔ Completed | Trial completion date: Dec 2021 ➔ Jun 2021

Trial completion • Trial completion date

Safety and Tolerability of NTX-101 in Korean Healthy Volunteers (clinicaltrials.gov) - P1; N=36; Active, not recruiting; Sponsor: Pinotbio, Inc.

Clinical • New P1 trial